- Home
- STTK vs INBX Comparison
STTK vs INBX Comparison
Compare STTK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- INBX
- Stock Information
- Founded
- STTK 2016
- INBX 2010
- Country
- STTK United States
- INBX United States
- Employees
- STTK N/A
- INBX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- INBX Health Care
- Exchange
- STTK Nasdaq
- INBX Nasdaq
- Market Cap
- STTK 56.8M
- INBX 218.9M
- IPO Year
- STTK 2020
- INBX 2020
- Fundamental
- Price
- STTK $1.12
- INBX $12.74
- Analyst Decision
- STTK Hold
- INBX Hold
- Analyst Count
- STTK 3
- INBX 1
- Target Price
- STTK $2.00
- INBX N/A
- AVG Volume (30 Days)
- STTK 182.2K
- INBX 74.4K
- Earning Date
- STTK 02-27-2025
- INBX 11-14-2024
- Dividend Yield
- STTK N/A
- INBX N/A
- EPS Growth
- STTK N/A
- INBX N/A
- EPS
- STTK N/A
- INBX 119.38
- Revenue
- STTK $6,435,000.00
- INBX $1,568,000.00
- Revenue This Year
- STTK $313.04
- INBX N/A
- Revenue Next Year
- STTK N/A
- INBX N/A
- P/E Ratio
- STTK N/A
- INBX $0.11
- Revenue Growth
- STTK 382.75
- INBX 19.24
- 52 Week Low
- STTK $0.94
- INBX $10.80
- 52 Week High
- STTK $11.76
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- INBX 32.23
- Support Level
- STTK $1.13
- INBX $13.57
- Resistance Level
- STTK $1.39
- INBX $16.83
- Average True Range (ATR)
- STTK 0.11
- INBX 0.94
- MACD
- STTK 0.00
- INBX -0.21
- Stochastic Oscillator
- STTK 18.18
- INBX 1.68
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.